Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: A real world observational study

by Linda Kemp, John Haughney, Neil Barnes, et al
Published 2010-07-01

Is the patient’s baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen?

by Michel Aubier, John Haughney, Olof Selroos, Onno C. P. van Schayck, Tommy Ekström, Juliette Ostinelli, Roland Buhl
Published 2011-10-01

Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study.

by David B Price, Richard Russell, Rafael Mares, Anne Burden, Derek Skinner, Helga Mikkelsen, Cherlyn Ding, Richard Brice, Niels H Chavannes, Janwillem W H Kocks, Jeffrey W Stephens, John Haughney
Published 2016-01-01

Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT

by Graham Devereux, Seonaidh Cotton, Shona Fielding, Nicola McMeekin, Peter J Barnes, Andy Briggs, Graham Burns, Rekha Chaudhuri, Henry Chrystyn, Lisa Davies, Anthony De Soyza, Simon Gompertz, John Haughney, Karen Innes, Joanna Kaniewska, Amanda Lee, Alyn Morice, John Norrie, Anita Sullivan, Andrew Wilson, David Price
Published 2019-07-01